Table 2.
Plasma measurements taken from the infused and non-infused arms at baseline, after 10 and 30 min of intrabrachial morphine (50 µg ml−1 min−1) and 60 min after discontinuation of morphine (90 min sample) as part of the tolerance study
| Baseline | 10 min | 30 min | 90 min | ||
|---|---|---|---|---|---|
| Histamine | Infused | 0.17 (0.02) | 0.88 (0.48) | 0.25 (0.04) | 2.85 (2.16) |
| Non-infused | 0.35 (0.05) | 0.30 (0.04) | 0.17 (0.02) | 0.24 (0.05) | |
| Tryptase | Infused | 5.1 (0.5) | 3.85 (0.3) | 4.4 (0.4) | 3.8 (0.4) |
| Non-infused | 5.7 (0.6) | 3.9 (0.3) | 5.7 (0.6) | 4.3 (0.4) | |
| vWF | Infused | 78.1 (33.9) | 61.3 (20.5) | 65.5 (21.8) | 34.9 (10.4) |
| Non-infused | 88.5 (31.9) | 42.2 (6.6) | 79.5 (30.5) | 56.6 (16.1) | |
| tPA | Infused | 4.0 (0.7) | 4.2 (0.7) | 4.2 (0.8) | 4.5 (0.8) |
| Non-infused | 5.3 (0.9) | 5.0 (0.9) | 4.5 (0.8) | 4.2 (0.8) | |
| PAI-1 | Infused | 6.0 (1.2) | 4.7 (0.9) | 5.0 (1.1) | 6.8 (2.3) |
| Non-infused | 7.1 (1.2) | 5.5 (1.2) | 5.0 (1.0) | 4.6 (1.8) |
Results are presented as mean ± SEM of eight subjects. vWF, von Willebrand factor; tPA, tissue plasminogen activator; PAI-1, plasminogen activator inhibitor.